Content about Actavis

MORRISTOWN, N.J. — Drug maker Actavis is partnering with QRxPharma to sell what the former called a novel pain drug in the United States.

The company said Wednesday that the two had signed a letter of intent to commercialize MoxDuo IR (morphine and oxycodone), which they plan to launch in third quarter 2012.

MORRISTOWN, N.J. — Actavis has launched an authorized generic drug for treating pain, the company said.

The drug maker announced Friday that it had started shipping morphine sulfate extended-release capsules, an authorized generic version of Kadian, which it also manufactures. The authorized generic product was launched on the same day as Watson Pharmaceuticals' generic version.

MORRISTOWN, N.J. — Actavis has launched its version of an epilepsy drug made by UCB.

The generic drug maker said it received approval from the Food and Drug Administration for levetiracetam extended-release tablets and commenced shipping the product following approval. The drug is the generic equivalent of Keppra XR.

U.S. sales of Keppra XR were about $161 million for the 12 months ended June 30, according IMS Health data.

MORRISTOWN, N.J. — The Food and Drug Administration has given final approval to a generic drug for insomnia made by Actavis, the drug maker said Monday.

The FDA approved the company’s zolpidem tartrate extended-release tablets in the 12.5-mg strength. The drug, which is a Schedule IV controlled substance, is a generic version of Sanofi’s Ambien CR. Actavis was the first company to launch a generic version of the drug in the 6.25-mg strength in October 2010.

WAYNE, Pa. — The Emerson Group announced that former Actavis executive Brad Blake has joined the company.

Blake will focus on Actavis, an Emerson client, and its business to continue the current strong relationship between the two companies. Additionally, Blake also will concentrate on other private-label business for Emerson and be responsible for Publix, Winn-Dixie and Dollar Tree.

Brad has been in the consumer packaged goods and over-the-counter business since 1982.

MORRISTOWN, N.J. — Actavis last week named Lisa Buono to lead its over-the-counter drug division as part of the company’s strategic expansion of the division.

As director of OTC, Buono will oversee the division’s day-to-day operations and will focus on identifying and capitalizing on new product opportunities. Actavis manufactures and distributes numerous nonprescription liquids, creams and ointments sold under the Actavis label and its customers’ own brands, as well as FeverAll brand acetaminophen suppositories.

MORRISTOWN, N.J. — Actavis has received approval from the Food and Drug Administration to market a generic version of a popular gastroesophageal reflux disease treatment.

The generic drug maker said it would market pantoprazole sodium delayed-release tablets in the 20-mg and 40-mg strengths. The drug is the generic equivalent of Pfizer's Protonix, which had U.S. sales of approximately $1.6 billion for the 12 months ended Dec. 31, 2010, according to IMS Health.

Actavis said it would distribute the drug soon.

MORRISTOWN, N.J. — On Tuesday, Lifetime Television’s program “The Balancing Act” will feature an appearance from Sarita Thapar, director of medical affairs for Actavis, to discuss the benefits of the company’s pediatric suppository FeverAll, Actavis announced last week.

MORRISTOWN, N.J. The Food and Drug Administration has approved a drug for treating insomnia made by Actavis, the generic drug maker said Monday.

Actavis announced the approval of zolpidem tartrate extended-release tablets in the 6.25-mg strength. The company has begun shipping the drug.

The drug is a generic version of Sanofi-Aventis’ Ambien CR, which had sales of around $129 million during the 12-month period ended in June, according to IMS Health.

MORRISTOWN, N.J. The Food and Drug Administration has approved a generic drug made by Actavis for treating attention deficit hyperactivity disorder, Actavis said Wednesday.

The FDA approved the drug maker’s atomoxetine hydrochloride capsules in the 10-mg, 18-mg, 25-mg, 40-mg, 60-mg, 80-mg and 100-mg strengths. The drug is a generic version of Eli Lilly’s Strattera, which had $532 million in sales during the 12-month period ended in June, according to IMS Health.

MORRISTOWN, N.J. Actavis on Tuesday announced the reintroduction of its FeverAll acetaminophen suppositories to retail following the completion of updates to the company’s manufacturing facility.

The brand will be marketed in publications read by new parents and healthcare professionals, the company stated.